About LinusBio
Our mission
Bringing precision exposome medicine for complex conditions lacking biomarkers with evidence of important clinical utility.
Originating from the world’s leading exposome laboratory at Mount Sinai Health System, LinusBio has developed a technology platform that builds on breakthroughs in exposome sequencing by trailblazing researchers Drs. Manish Arora, Christine Austin and Paul Curtin.
The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease, oncology and more.
"A key reason that we decided to focus on autism is the dramatically different developmental trajectory when the condition is detected early in life, and the child receives interventions tailored to meet their needs. The positive impact on children and their families can be substantial."
Roadmap
Milestones and achievements
A pivotal year of growth
The world’s first Institute for Exposomic Research established at Mount Sinai in 2013 with Manish Arora, PhD as the co-founder and director of environmental exposure and precision environmental medicine laboratories, leading a team of over 50 scientists advancing research in a vast array of diseases that are national health priorities, including autism, ALS, cancers, and gastrointestinal disorders.
Awarded the U.S. Presidential Early Career Award
Dr. Manish Arora awarded the U.S. Presidential Early Career Award for Scientists and Engineers (PECASE)
NIH grants of $25 million
NIH grants of $25 million awarded to Dr. Arora and researchers at the Mt. Sinai Institute for Exposomic Research
LinusBio INC
- LinusBio incorporated
- Initial patents filed
Partnerships
- Spinoff from Mt. Sinai completed, and worldwide license and collaboration agreement announced
- Strategic partnerships with two global biopharma companies initiated
- FDA Breakthrough
Device designation awarded to StrandDxTM – ASD to assess the likelihood of autism in children < 18 months old and to aid in diagnosis
of autism
- Medical Device Regulatory Pathway for StrandDx™- ASD continued with FDA feedback and meetings
- Closed Series A financing round with Bow Capital and GPV as co-leads
A2 funding
- Closed Series A2 funding round with increased valuation
- Announced partnership with Y.A.C. Holdings, Japan, to scale lab output
StrandDx™- ASD
- Establish licensed proprietary laboratory to make StrandDx™- ASD available as a laboratory developed test for pilot programs
- Determine novel molecular endpoints for collaboration partners’ drug discovery and clinical trials
Team
Meet the minds driving innovation at LinusBio
Our leadership team combines expertise, vision, and dedication to push the boundaries of biomedics. Learn more about the individuals shaping LinusBio's mission to transform healthcare through groundbreaking research and development.
Linus Bio team
Board members
